EVM
SUPN icon

Eaton Vance Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Eaton Vance Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,315
Closed -$68K – 2609
2021
Q4 		$68K Buy
2,315
+52
+2% +$1.58K ﹤0.01% 1982
2021
Q3 		$0 Sell
2,263
-178
-7% -$4.78K ﹤0.01% 2630
2021
Q2 		$75K Buy
2,441
+2,017
+476% +$61.8K ﹤0.01% 2017
2021
Q1 		$11K Buy
+424
New +$11.9K ﹤0.01% 2338

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Eaton Vance Management's SUPN Position: Q1 2022 in Review

Eaton Vance Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2022, closing a stake of 2,315 shares — an estimated $68K sold.

Eaton Vance Management first reported a position in SUPN in Q1 2021 and held it in 4 quarters. The position peaked at $75K in Q2 2021. 230 funds tracked by Wall St. Rank hold SUPN as of Q1 2022.

  • Eaton Vance Management reported no remaining Supernus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 2,315 Supernus Pharmaceuticals shares in Q1 2022, an estimated $68K.
  • Eaton Vance Management first reported a position in Supernus Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Eaton Vance Management's Supernus Pharmaceuticals position peaked at $75K in Q2 2021.
  • 230 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.